相关实验视频

Updated: May 13, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K

在转移性乳腺癌中检测ESR1突变的动力学和决定因素

L Cabel1, F Berger2, T Bachelot3

  • 1Department of Medical Oncology, Institut Curie, Paris, France.

Annals of oncology : official journal of the European Society for Medical Oncology
|November 19, 2025
PubMed
概括

早期针对血液ESR1突变 (bESR1-mut) 使用富勒佛兰特有益于晚期乳腺癌患者. 识别bESR1-mut检测因素有助于选择患者接受ESR1-向治疗.

关键词:
在CDK4/6中使用.这是ESR1突变.芳香酶抑制剂 芳香酶抑制剂生物标志物 生物标志物乳腺癌 乳腺癌 乳腺癌

更多相关视频

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

17.3K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.3K

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...